Global Hyperuricemia Therapeutics Pipeline Report H1 2017 - Review of 8 Companies & Drug Profiles - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hyperuricemia - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Hyperuricemia - Overview
4. Hyperuricemia - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Hyperuricemia - Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type
15. Hyperuricemia - Companies Involved in Therapeutics Development

• Allena Pharmaceuticals Inc
• AstraZeneca Plc
• CymaBay Therapeutics Inc
• Jiangsu Hengrui Medicine Co Ltd
• Nippon Chemiphar Co Ltd
• Nobelpharma Co Ltd
• Polaris Pharmaceuticals Inc
• Teijin Pharma Ltd
  

For more information about this report visit http://www.researchandmarkets.com/research/bmk3x6/hyperuricemia